GlaxoSmithKline, 23andMe team up on genetics-driven drug research
British drug giant GlaxoSmithKline is investing $300 million in consumer genetics company 23andMe, forging a four-year collaboration to discover medicines using human genetics as a guide.
The partnership establishes GSK as 23andMe’s exclusive collaborator for drug target discovery, the companies said Wednesday. It comes with an option to extend for a fifth year, and funding and proceeds will be split equally.
Enjoying this research? Get deeper insights like this delivered every other week.
Every other week our Premium Members receive deep dives like this alongside Rhonda's commentary and 8+ other hand-picked papers.
The announcement comes as GSK embarks on a new research strategy under new Chief Scientific Officer Hal Barron, a drug industry veteran. The new approach focuses on the immune system, genetics and advanced analytics and technology.